Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs

Hampshire
19 June 2013 16:31


Hertfordshire
19 June 2013 16:30


Berkshire
19 June 2013 16:25

Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Joe Moore
Operations Director
joe@zenopa.com
+44 1494 818011

Testimonials
“I contacted Zenopa directly when searching for a new job. They were extremely helpful, approachable, professional and had a wealth of knowledge and contacts enabling me to get the interviews and subse...”
Tom, 2011

Boehringer Ingelheim set to acquire biotech firm

19 June 2008 00:00 in Pharmaceutical Company Restructures

Boehringer Ingelheim (BI) has agreed a deal that will see it acquire the biotech firm Actimis Pharmaceuticals, it has been announced.

The deal is described as being a structured buyout and its completion will depend on Actimis being able to progress its leading drug compound through to phase III clinical trials.

If the relevant compound, which is a novel target for asthma and allergic rhinitis, does make it to phase III tests then BI will take control of the entire company at a cost of around £250 million.

Dr Andreas Barner, vice-chairman of the board corporate division pharma research, at BI, said: "Actimis' compound provides an innovative addition to Boehringer Ingelheim's portfolio of development candidates for the potential treatment of respiratory diseases."

BI describes its companies as being research-driven and the group currently employs close to 40,000 people worldwide.

Other news stories from 19/06/2008

Recent news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency
             
© Copyright 2013 Zenopa Ltd